立体定向体部放疗在寡转移性肾细胞癌治疗中的作用
该回顾性研究分析了2004至2016年接受立体定向体部放疗的58例肾细胞癌寡转移患者(共73处转移灶),全部患者原发肿瘤已切除且转移灶不超过3个。12和18个月局部控制率均为90.2%,无进展生存率分别为46.2%和35%。立体定向体部放疗安全性可接受且局部控制有效,但尚需前瞻性研究评估对生存和生活质量的影响。
要点
- 寡转移性肾细胞癌患者接受立体定向体部放疗的12和18个月局部控制率均为90.2%。
- 异时性和单发转移与更好的无进展生存相关。
- 立体定向体部放疗前接受全身治疗可改善透明细胞癌患者的局部控制。
核心结论
- 立体定向体部放疗可作为寡转移性肾细胞癌的安全治疗选择,并提供有效的局部控制。
研究设计与样本
- 回顾性分析2004至2016年58例(73处转移灶)接受立体定向体部放疗的肾细胞癌患者,入组条件为转移灶不超过3个且原发肿瘤已切除。
主要发现
- 全部患者均为肾细胞癌,其中透明细胞型占82.7%。
- 39处转移灶(53.4%)位于肺部,19处(26%)位于淋巴结,骨转移占9.5%、肝转移占4.1%、肾上腺转移占6.8%。
- 中位随访16.1个月(范围3.5至157.1个月)。
- 12和18个月局部控制率均为90.2%。
- 12和18个月无进展生存率分别为46.2%(95%CI 32.2-59)和35%(95%CI 21.4-48.9)。
关键数值与推荐
- 单因素和多因素分析显示异时性和单发转移预测更好的无进展生存。
- 立体定向体部放疗前全身治疗预测透明细胞癌患者局部控制改善。
临床怎么用
- 对于原发肿瘤已切除、转移灶不超过3个的肾细胞癌患者,可考虑立体定向体部放疗以实现局部控制。
局限性
- 需前瞻性研究评估立体定向体部放疗对生存和生活质量的影响。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Kidney cancer has been increasing 1.7% annually. Renal cell carcinoma is the most common kidney cancer and it can metastasize. Our aim was to analyze patients treated with stereotactic body radiation therapy of renal cell carcinoma metastases. MATERIALS AND METHODS: A total of 58 patients (73 lesions) were treated from 2004 to 2016. Patients were candidates for analysis if a maximum of 3 metastases were diagnosed and the primary tumor was resected. Toxicity was classified according to Common Terminology Criteria for Adverse Events version 3. RESULTS: All patients had renal cell carcinoma, in particular the clear cell type in 82.7%. A total of 39 metastases (53.4%) were located in the lungs and 19 (26%) were in the lymph nodes. Less common were metastases to bone (9.5% of cases), the liver (4.1%) and the adrenal gland (6.8%). Median followup was 16.1 months (range 3.5 to 157.1). The local control rate at 12 and 18 months was 90.2% and 90.2%, respectively. The progression-free survival rate at 12 and 18 months was 46.2% (95% CI 32.2-59) and 35% (95% CI 21.4-48.9), respectively. On univariate and multivariable analyses metachronous and single metastases predicted better progression-free survival. Systemic therapy before stereotactic body radiation therapy predicted improved local control in clear cell cases. CONCLUSIONS: Stereotactic body radiation therapy can be considered a safe approach and it provides effective local control of oligometastatic renal cell carcinoma. However, future prospective studies are necessary to evaluate the impact on survival and quality of life.
引用
- Franzese C, Franceschini D, Di Brina L, et al. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma. J Urol. 2019. PMID: 30179619. doi:10.1016/j.juro.2018.08.049
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。